Use of recombinant factor VIIA for control of combat-related haemorrhage.

Woodruff SI, Dougherty AL, Dye JL, Mohrle CR, Galarneau MR
Emerg Med J 2010;27(2):121-124.
NATA Rating :
Review by : J.-F. Hardy
NATA Review

The authors should be congratulated for presenting their negative results. The success rate of approximately 70% in both groups is the same as that reported in numerous case series and registers supporting the “efficacy” of rFVIIa in various contexts. Unfortunately, despite three negative randomized controlled trials in trauma (two published, one unpublished), rFVIIa continues to be used for this indication.

– Jean-Franois Hardy

Consent Management Platform by Real Cookie Banner